Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate
Heidelberg Pharma AG today announced that its partner Magenta Therapeutics, Cambridge, MA, USA, exercises its option to further develop a target molecule, and will now continue the development of an Antibody Targeted Amanitin Conjugate based on the target molecule within an exclusive licensing.